--- schema_version: "secwatch.filing_event.v1" accession: "0001683168-22-008705" form_type: "8-K" ticker: "PMCB" cik: "0001157075" company_name: "PharmaCyte Biotech, Inc." filed_at: "2022-12-30T23:59:59+00:00" generated_at: "2026-06-20T21:20:29.405370+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.6 calibrated_materiality_score: 0.6 confidence: "high" source: SEC EDGAR --- # PharmaCyte Biotech shareholders approve reverse stock split, increase authorized shares to 133M ## Summary - Reverse stock split at ratio of 1:5 to 1:20 approved with 11,385,563 votes for, 2,067,045 against. - Authorized common shares increased from 33,333,334 to 133,333,334 approved with 11,020,851 for. - 2022 Equity Incentive Plan approved with 6,532,612 for, 1,162,890 against. - All five director nominees elected; Armanino LLP ratified as auditor for FY ending April 30, 2023. - Advisory vote on executive compensation passed; frequency of every year selected by 7,493,683 votes. ## SEC filing metadata - accession: 0001683168-22-008705 - form_type: 8-K - ticker: PMCB - cik: 0001157075 - company_name: PharmaCyte Biotech, Inc. - filed_at: 2022-12-30T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.6 - calibrated_materiality_score: 0.6 - confidence: high - sec_items: 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316822008705/0001683168-22-008705-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316822008705/pharmacyte_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001683168-22-008705 - JSON: https://secwatch.observer/filing/0001683168-22-008705.json - Plain text: https://secwatch.observer/filing/0001683168-22-008705.txt ## Key facts - Shareholder Votes PharmaCyte Biotech, Inc. shareholders approved Approval of amendment to Articles of Incorporation to effect a reverse stock split at the 2022-12-28 meeting. - Proposal: reverse split - Outcome: passed - Meeting: 2022-12-28 source text: Proposal 3. Approval of Reverse Stock Split. The approval of an amendment to the Company’s Articles of Incorporation, as amended (the “Charter”) to effect a reverse stock split of the Company’s common stock at a ratio of one new share for every five to twenty shares outstanding. For Against Abstain 11,385,563 2,067,045 22,354 evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822008705/0001683168-22-008705-index.htm - Shareholder Votes PharmaCyte Biotech, Inc. shareholders approved Election of five directors to hold office until 2023 annual meeting at the 2022-12-28 meeting. - Proposal: director election - Outcome: passed - Meeting: 2022-12-28 source text: Proposal 1. Election of Directors. The election of five directors, each to hold office until the 2023 annual meeting of stockholders or until their respective successor is elected and qualified. Nominee For Withheld Broker Non-Votes Joshua N. Silverman 7,462,403 352,070 5,660,489 Jonathan L. Schechter 7,475,332 339,141 5,660,489 Michael M. Abecassis 7,381,147 433,326 5,660,489 Robert Weinstein 7,443,492 370,981 5,660,489 Wayne R. Walker 7,421,985 392,488 5,660,489 evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822008705/0001683168-22-008705-index.htm - Shareholder Votes PharmaCyte Biotech, Inc. shareholders approved Ratification of Armanino LLP as independent registered public accounting firm for fiscal year ending April 30, 2023 at the 2022-12-28 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2022-12-28 source text: Proposal 5. Ratification of Selection of Independent Registered Public Accounting Firm. The ratification of the selection by the audit committee of the Board of Armanino LLP as the independent registered public accounting firm of the Company for the fiscal year ending April 30, 2023. For Against Abstain 13,124,245 256,083 94,634 evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822008705/0001683168-22-008705-index.htm - Shareholder Votes PharmaCyte Biotech, Inc. shareholders approved Non-binding advisory vote to approve executive compensation at the 2022-12-28 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2022-12-28 source text: Proposal 6. Approval of Executive Compensation. The approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. For Against Abstain Non-Votes Broker Non-Votes 6,554,590 720,564 529,347 9,972 5,660,489 evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822008705/0001683168-22-008705-index.htm - Shareholder Votes PharmaCyte Biotech, Inc. shareholders approved Approval of amendment to Charter to increase authorized shares of common stock from 33,333,334 to 133,333,334 at the 2022-12-28 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2022-12-28 source text: Proposal 4. Approval of the Increase of Authorized Shares of Common Stock The approval of an amendment to the Charter to increase the total number of authorized shares of common stock from 33,333,334 to 133,333,334. For Against Abstain 11,020,851 2,399,825 54,286 evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822008705/0001683168-22-008705-index.htm - Shareholder Votes PharmaCyte Biotech, Inc. shareholders approved Non-binding advisory vote on frequency of future advisory votes on executive compensation at the 2022-12-28 meeting. - Proposal: say on pay frequency - Outcome: passed - Meeting: 2022-12-28 source text: Proposal 7. Approval of Frequency of Future Votes to Approve Executive Compensation The approval, on a non-binding advisory basis, of the frequency of future advisory votes to approve the compensation of the Company’s named executive officers. Every Year Every Two Years Every Three Years Abstain Broker Non-Votes 7,493,683 72,255 134,022 114,513 5,660,489 evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822008705/0001683168-22-008705-index.htm - Shareholder Votes PharmaCyte Biotech, Inc. shareholders approved Approval of PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan at the 2022-12-28 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2022-12-28 source text: Proposal 2. Approval of PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan The approval of the PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan. For Against Abstain Broker Non-Votes 6,532,612 1,162,890 118,971 5,660,489 evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822008705/0001683168-22-008705-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.